GC 310
Alternative Names: GC-310Latest Information Update: 18 Nov 2022
At a glance
- Originator GeneCradle Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 12 Oct 2022 Preclinical trials in Unspecified in China (Parenteral), prior to October 2022 (GeneCradle Therapeutics pipeline, October 2022)